CD14 and myeloid sarcoma: Nlrx1 mRNA expression is significantly increased in CD14+ PBMCs in relapsing-remitting MS patients, and the identification of rare NLRX1 mutations in MS patients, such as p.Lys172Asn, p.Glu192Ter, and p.Arg860Trp links NLRX1 genetic variants to the incidence of MS in humans.